Trump Administration Moves to Loosen Marijuana Restrictions, Raising Concerns Over Public Safety
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Trump administration has controversially reclassified state-licensed medical marijuana to Schedule III, a move that acknowledges its medical use and eases regulations, despite ongoing concerns about marijuana's risks and the influence of the cannabis industry.
In a significant and contentious policy shift, the Trump administration has reclassified state-licensed medical marijuana from Schedule I to Schedule III under federal drug laws. This change, which acknowledges the medical use of cannabis and reduces regulatory barriers, stops short of full federal legalization but nonetheless marks a concerning step toward normalizing a drug with well-documented risks.
Acting Attorney General Todd Blanche signed the order, stating that the Department of Justice is 'delivering on President Trump's promise' to expand medical treatment options. Blanche emphasized that the rescheduling action allows for research on the safety and efficacy of cannabis, but critics warn this could open the door to further erosion of drug laws and public safety standards.
The reclassification legitimizes medical marijuana programs in the 40 states that have adopted them and creates an expedited system for state-licensed medical marijuana producers and distributors to register with the U.S. Drug Enforcement Administration. It also means cannabis researchers will no longer face penalties for obtaining state-licensed marijuana or marijuana-derived products for their work. Furthermore, state-licensed medical marijuana companies can now deduct business expenses on their federal taxes, a benefit that critics argue will primarily help large cannabis corporations and their investors.
Skeptics, such as Kevin Sabet, chief executive of Smart Approaches to Marijuana, argue that while marijuana research is necessary, there are many ways to increase knowledge without giving tax breaks to wealthy cannabis companies and sending a confusing message about marijuana's dangers to the public. Sabet expressed concern that policy is increasingly being shaped by marijuana CEOs and investors, rather than prioritizing public health and safety.
Marijuana or marijuana-derived products not distributed through a state medical marijuana program will continue to be classified in Schedule I, but this reclassification sets a precedent that could lead to further loosening of drug laws. The Trump administration plans to initiate a new administrative hearing process in June to consider the broader rescheduling of marijuana, a move that many fear could undermine efforts to combat drug abuse and protect American communities.